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Abstract
Background: Recent data have suggested that 18 million of new sepsis cases occur each year
worldwide, with a mortality rate of almost 30%. There is not consensus on the clinical definition of
sepsis and, because of lack of training or simply unawareness, clinicians often miss or delay this
diagnosis. This is especially worrying; since there is strong evidence supporting that early treatment
is associated with greater clinical success. There are some difficulties for sepsis diagnosis such as
the lack of an appropriate gold standard to identify this clinical condition. This situation has
hampered the assessment of the accuracy of clinical signs and biomarkers to diagnose sepsis.
Methods/design:  Cross-sectional study to determine the operative characteristics of three
biological markers of inflammation and coagulation (D-dimer, C-reactive protein and Procalcitonin)
as diagnostic tests for sepsis, in patients admitted to hospital care with a presumptive infection as
main diagnosis.
Discussion: There are alternative techniques that have been used to assess the accuracy of tests
without gold standards, and they have been widely used in clinical disciplines such as psychiatry,
even though they have not been tested in sepsis diagnosis. Considering the main importance of
diagnosis as early as possible, we propose a latent class analysis to evaluate the accuracy of three
biomarkers to diagnose sepsis.
Background
Sepsis is defined as host response to infection and it is an
important cause of morbidity and mortality all around
the world. Recent data have suggested that 18 million of
new sepsis cases occur each year worldwide, with a mor-
tality rate of almost 30% [1]. Incidence has risen due to
aging of the population and the higher incidence of
immunosuppressive conditions such as Acquired Immun-
odeficiency Syndrome (AIDS), chemotherapy for cancer,
and use of invasive devices [2]. Sepsis costs on average US
$ 22,000 per patient; in the United States US $16.7 billion
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are spent each year in sepsis care, which means a deep
impact on financial resources [3].
The surviving sepsis campaign, a collaborative attempt from
three major critical care organizations, issued a call for
global action against sepsis. This Campaign pointed out
sepsis diagnosis as a fundamental challenge [1]. There is
no consensus on the clinical definition of sepsis and,
because of lack of training or simply unawareness, clini-
cians often miss or delay this diagnosis. This is especially
worrying; since there is strong evidence supporting that
early treatment is associated with greater clinical success
[4,5].
Ideally, "sepsis findings"-symptoms, signs, or biomarkers-
should be compared with a "gold standard" test that is
100% sensitive and specific. This type of test rarely exists
in clinical practice, but often there is a single test that is at
least accurate enough to serve as a reference standard.
Even this is not available for sepsis diagnosis, as microbi-
ology is not enough sensitive and laboratory tests are not
specific for using as reference standards. The lack of a ref-
erence test has hampered the assessment of the accuracy
of clinical signs and biomarkers to diagnose sepsis. How-
ever, some clinical areas have dealt with this inconven-
ient. Psychiatrists make diagnoses without the benefit of
laboratory, radiographies, or pathology reports. The lack
of any reference standard in psychiatry has been overcome
by using techniques that avoid the need for comparison
with a single accurate test. These techniques can be
broadly divided into latent class analysis (LCA) and Baye-
sian analysis [6]. LCA has been used widely in psychiatry
as well as other disciplines [7-11] but, it has not been yet
applied to the evaluation of the accuracy of clinical assess-
ment in sepsis.
The problem with the definitions
Over the last three decades, the syndrome now commonly
referred to sepsis has alternately been called septicemia
[12], sepsis syndrome [13] and, simply sepsis, the last def-
inition described jointly with the closely related concept
of systemic inflammatory response syndrome (SIRS) [14].
SIRS is considered to be present when patients present
more than one of the following four clinical findings:
1) Body temperature > 38°C or < 36°C;
2) Heart rate > 90 beats min-1;
3) Hyperventilation evidenced by a respiratory rate > 20
breaths min-1 or PaCo2 < 32 mm Hg;
4) White blood cell (WBC) count > 12,000 cells μL-1 or <
4,000 μL-1 or with > 10% immature forms.
A 1992 statement from the American College of Chest
Physicians/Society of Critical Care Medicine (ACCP/
SCCM) Consensus Conference, hypothesized that sepsis
is a systemic response to infection; where infection is
defined as an invasion process of a pathogenic or poten-
tially pathogenic microorganisms to normally sterile tis-
sue, fluids or body cavities [14]. According to this
definition, a diagnosis of sepsis requires the presence of
both infection and SIRS. Following the same model, sep-
sis with evidence of organic dysfunction would be charac-
terized as severe sepsis; and sepsis with acute circulatory
failure characterized by persistent hypotension unex-
plained by other causes, would be defined as septic shock.
However, as we showed in a recent work [15] and also as
has been repeatedly pointed out by several experts
[16,17], despite the fact that the SIRS definition considers
that a systemic inflammatory response can be triggered by
a variety of conditions (infectious and noninfectious),
this particular combination of criteria are neither specific
nor sensitive enough to be useful for making medical
decision or to establish an accurate operative definition
for the syndrome.
Nowadays, although no epidemiological evidence exists
to support a change in the syndrome's definition (a sys-
temic response to infection); it seems clear that the list of
signs and symptoms of sepsis should be expanded to
reflect clinical bedside experience. In this regard, the last
International Sepsis Definition Conference [18] stated that a
diagnosis of sepsis should be considered in the presence
of a documented or suspected infection, concurrent with
some markers of general illness, inflammation, hemody-
namic disturbance, organ dysfunction or tissue perfusion
abnormalities (Table 1.)
Notwithstanding the lack of conclusive criteria for sepsis,
the definitions of severe sepsis (sepsis complicated by
organ dysfunction) and septic shock (systolic blood pres-
sure below 90 mm Hg or a reduction of > 40 mm Hg from
baseline despite adequate volume resuscitation, in the
absence of other causes for hypotension) remain undis-
puted. Unfortunately, this simple classification and range
of definitions have strong limitations for precise charac-
terization of sepsis, and mainly for the early staging of
patients. Hence, the International Sepsis Definitions Confer-
ence  [18], on the basis of ideas arisen from the Fifth
Toronto Sepsis Roundtable [19], has proposed a classifica-
tion scheme called -PIRO-. This staging system is aimed to
be used for stratification of patients based on their Predis-
position, the type and extent of the Infection, the nature
and magnitude of the host Response, and the degree of
associated Organ dysfunction.BMC Infectious Diseases 2008, 8:18 http://www.biomedcentral.com/1471-2334/8/18
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The potential utility of this PIRO model lies in being able
to discriminate morbidity arising from infection, which
seems relatively mild, and morbidity arising from the host
response  to infection. Such a difference is critical since
interventions that modulate the host response may
impact adversely on the ability to contain an infection
[19,20]. On the other hand, interventions that target
exclusively the infection are unlikely to be beneficial if the
morbidity is being driven by the host response. Besides,
the same staging system may also provide a conceptual
framework to improve the diagnosis process in sepsis.
Specifically, appropriate characterization of Infection
(injury) and Response  (nature and magnitude of host
responses) are sine qua non conditions to define, from a
clinical point of view, the challenging spectrum of sepsis.
Infection and host response in sepsis
There are several important issues in the pathogenesis of
septic phenomenon. First, the host response, more than
the nature or type of infection, appears as a critical deter-
minant in patient prognosis. Second, monocytes and
endothelial cells play a central role in initiating and per-
petuating the host response. Third, sepsis is clearly associ-
ated with the simultaneous activation of the
inflammatory and coagulation cascades, and most of their
components are markers or mediators in the host
response [19]. As corollary, the effort to defeat and elimi-
nate pathogens may generate collateral damage on nor-
mal tissues, resulting in organ dysfunction and death [21].
The functional relationship between coagulation and
inflammation within the pathogenic framework of sepsis
has been recently dissected in extensum but, as yet, it is not
completely understood [22-26]. In short, infection pro-
motes coagulation via a large number of molecular and
cellular mechanisms. The primary mechanism responsi-
ble for this pro-coagulant activity, however, may be the
generation by monocytes and macrophages of pro-
inflammatory cytokines, especially Interleukin 6 (IL-6),
Interleukin 1β(IL-1β) and tumor necrosis factor (TNF).
These cytokines, in turn, induce Tissue Factor (TF) expres-
sion in monocytes and endothelial cells, whereby extrin-
sic coagulation cascade is initiated [21,27]. At the same
time, many clotting system components, such as
thrombin, factor Xa and the TF-factor VIIa complex, work-
ing in conjunction with the inhibition of endogenous
anticoagulants as antithrombin and activated protein C,
act as boosters for the systemic inflammatory response in
sepsis [28].
From this close interplay between inflammation and
coagulation, which is a recognized way toward organ dys-
function and mortality, emerges the rationale to charac-
terize the host response to infection. Indeed, the only
effective complementary therapy for sepsis discovered on
the last twenty years, Drotrecogin alfa (activated), a
recombinant human activated protein C, is focused on
modulation of the systemic inflammatory, pro-coagulant,
and fibrinolytic responses [29]. Thus, although the clini-
cal manifestations of inflammation and coagulation may
be elusive, their biochemical features may be more con-
sistent and constitute an attractive manner to characterize
the syndrome. Three potential biomarkers have shown
regular presence in systemic infections: C-reactive protein
(CRP), procalcitonin (PCT), and D-dimer; the latter as an
unspecific signal of coagulation activation [22,30,31]. So
far, however, no large prospective studies support any of
them as a single independent criterion for sepsis.
CRP is a typical acute-phase reactant and also is a largely
studied marker of infection [30,32-34]. This protein binds
to several polysaccharides present in bacteria, fungi and
parasites, in the presence of calcium. These complexes
activate the classical complement pathway, acting as
opsonins and promoting phagocytosis. Recently, a cal-
cium-dependent complex between CRP and very low den-
sity lipoprotein (VLDL) was also discovered in sera from
critically ill patients, and it was associated with early
changes in the activated partial thromboplastin time
(aPTT) test, the development of disseminated intravascu-
lar coagulation (DIC), and the risks of mortality and sep-
sis [35,36]. CRP is predominantly synthesized by the liver
Table 1: Potential sepsis related markers (modified from 
reference 18)
General Variables
Temperature > 38.3°C or < 36°C
Heart rate > 90 beats min-1
Tachypnea (respiratory rate > 20 breaths min-1 in adults)
Altered mental status
Inflammatory variables
WBC > 12,000 μL-1, < 4,000 μL-1 or with > 10% immature forms
Plasma C-reactive protein > 2 SD above the normal value
Plasma procalcitonin > 2 SD above the normal value
Hemodynamic variables
Systolic blood pressure < 90 mm Hg or mean arterial blood pressure 
< 70 mm Hg
Mixed venous oxygen saturation > 70%
Cardiac index > 3.5 L*min-1*M-23
Organ dysfunction variables
PaO2/FIO2 < 300
Urine output < 0.5 mL*kg-1*hr-1 or creatinine increase > 0.5 mg/dL
International normalized ratio (INR) > 1.5 or aPTT > 60 secs
Platelet count < 100,000 μL-1
Plasma total bilirrubin > 4 mg/Dl
Tissue perfusion variables
Hyperlactatemia > 1 mmol/L
Decreased capillary refill or mottlingBMC Infectious Diseases 2008, 8:18 http://www.biomedcentral.com/1471-2334/8/18
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and mainly in response to IL-6, with which exists a good
correlation between serum levels. The secretion of CRP
begins within 4–6 hours of the stimulus, doubling every 8
hours and peaking at 36–50 hours. After disappearance or
removal of the stimulus, CRP falls rapidly, as it has a half-
life of 19 hours. However, CRP can remain elevated, even
for very long periods, if the underlying cause of the eleva-
tion persists. Only those interventions affecting the
inflammatory process responsible for the acute phase
reaction can change the CRP level. Changes may be very
helpful in diagnosis as well as in monitoring response to
therapy, as CRP levels are only determined by the rate of
synthesis [30].
PCT is a 116-amino acid pro-hormone, which have been
shown to be an extremely useful marker in sepsis, whether
blood cultures are positive or negative; and in sepsis-like
conditions such as severe burns, pancreatitis, inhalation
injury, severe mechanical trauma after extensive surgery,
and also in some infections of nonbacterial causation as
severe malaria or systemic fungal infection [31,37-40].
Serum levels of PCT are frequently increased in sepsis
patients, sometimes attain levels several thousand-fold
normal, and these high levels often persist for long peri-
ods of time. Moreover, the levels often correlate positively
with the severity of the condition and mortality [39,41].
In septic states PCT is produced throughout the body, and
although experimentally is toxic to septic animals, it is not
known how this polypeptide or its components might
worsen the septic process. Furthermore, its normal physi-
ologic actions, if any, are unknown [31].
As mentioned, activation of coagulation cascade is a com-
mon and early phenomenon in the development of sep-
sis, and this fact supports the use of anticoagulant
treatments as potentially useful interventions. The final
pathway in the coagulation system is characterized by the
following reactions [42]: in the presence of thrombin,
fibrinogen is cleaved to form fibrin monomers, which are
subsequently stabilized by thrombin-activated factor XIII.
Covalent cross-linkages in the D-domain region of fibrin
produce an insoluble fibrin clot. The presence of the fibrin
clot, in turn, triggers plasmin to lyse the clot as well as
fibrinogen. Whereas fibrinogenolysis leads to fibrinogen-
degradation products, lysis of the fibrin clot generates
cross-linked fibrin-degradation products containing D-
dimer. Generally, a finding of more than 500 ng of D-
dimer per milliliter is considered abnormal, and such lev-
els are present in virtually all of patients with sepsis
[25,28]. In fact, the Drotrecogin trial showed that parallel
with a decrease in serum IL-6, plasma D-dimer levels were
significantly lower in patients in the intervention group
than in patients in the placebo group on days 1 through 7
after the start of the infusion [29].
Diagnostic criteria in sepsis will be judged successful if cli-
nicians regard them as an aid for decision-making at the
bedside. Furthermore, any laboratory dependent criteria
should use assays that are both, widely available and
affordable everywhere. This diagnostic scheme requires
sufficient sensitivity to identify most patients with the
syndrome, while minimally sacrificing inevitable specifi-
city [19,43]. According to conclusions addressed in the
International Sepsis Definition Conference [18], "the opera-
tional definitions of sepsis may be refined and tested in
the future as we increase our understanding of the immu-
nologic and biochemical characteristics of these condi-
tions." Therefore, a sound combination of inflammation
and coagulation markers may provide the appropriate
characterization to clinical suspicion in sepsis.
Objectives
We aim to estimate the operative characteristics (sensitiv-
ity, specificity, predictive values and likelihood ratios) of
three biological markers of inflammation and coagulation
as diagnostic tests for sepsis, in patients admitted to hos-
pital care with a presumptive infection as main diagnosis.
Operative characteristics of individual markers will be
estimated and three different combinations (CRP +DD,
PCT+DD, CRP +PCT) will be evaluated as well.
Methods/Design
Study design
Cross-sectional study to determine the operative charac-
teristics of a diagnostic test.
Setting
Emergency Room (ER) service at the "Hospital Universi-
tario San Vicente de Paúl" (Medellín, Colombia). This is a
550-bed, fourth level University Hospital, and is a refer-
ence institution for a region including approximately 3
million habitants. There are three intensive care unities
(Surgical, Medical and Cardiovascular)
Study population
Inclusion criteria
1. Patients hospitalized by the ER within 24 hours before
admission to the study.
2. Aged 18 years or older
3. At least one of the following causes should be the main
admission diagnosis to the hospital: a) any kind of infec-
tious disease (confirmed or suspected), b) fever of
unknown origin, c) delirium or any kind of encephalopa-
thy of unknown origin, d) acute hypotension not
explained by hemorrhage, myocardial infarction, stroke
or heart failure, e) Adult Respiratory Distress Syndrome or
f) multiple organ failure.BMC Infectious Diseases 2008, 8:18 http://www.biomedcentral.com/1471-2334/8/18
Page 5 of 9
(page number not for citation purposes)
Exclusion criteria
1. Negative of the patients, their families or the physician
to be part of the study.
2. Antimicrobial treatment before the beginning of the
study received in other medical institution
3. Medical decision to treat the patient ambulatory or in
other different institution within 24 hours of the study
beginning.
The study population will be selected by an active search
of possible candidates admitted to the ER. This search will
be carried out permanently by research assistants with
health care training. This study population widely defined
but relevant for our research question, will allow us to
study all the severity spectrum of this condition: patients
with mild to severe infectious diseases, probably or con-
firmed cases by microbiology tests, and finally patients
whom infectious causes will be discard as the responsible
of hospital admission.
Gold standard tests
Three gold standard tests will be considered in the analysis
and their results will be determined without knowledge of
the CRP, PCT and DD results. These gold standards will
allow defining two study groups: patients with infection
and/or sepsis (Positive by "Gold Standard") and patients
without confirmed infection or sepsis (Negative by "Gold
Standard"). The three gold standards are the following:
1. Presence of infection defined by microbiological confir-
mation
2. Clinical consensus defined by three experts with clinical
practice in Internal medicine, Infectious diseases and
Intensive care. This consensus will follow the criteria for
nosocomial infection defined by the CDC; and the criteria
proposed by the last International conference of sepsis
definitions [18]. This criterion will be defined at the end
of the first week of the patient admission to the study in
order to have definitive results of microbiological tests. In
this regard, this clinical "Gold Standard" let to define
three groups: confirmed sepsis by microbiology, probably
sepsis without microbiological evidence, and patients
without sepsis.
3. Likelihood of sepsis diagnosis in the study population
according to a latent class analysis (LCA).
Procedures and data collection (Table 2)
Definitions of the evaluations
Clinical record review
The main clinical diagnosis, the symptoms, the signs and
the clinical data registered in the admission clinical record
in the ER will be used in the screening process and the
selection of the study population. The researchers will not
have any participation in the decision about hospitalary
or ambulatory treatment, as this responsibility is exclu-
sively of the ER medical team.
Inform consent
Research assistants will describe the objective and the
research procedures of the study to the potential partici-
pants. According to the local Institutional Review Board
(Ethical Committee, Medical Research Center, Universi-
dad de Antioquia), signed consent will be waived and oral
approval will be obtained from all patients willing to par-
ticipate.
APACHE II score
This is a recognized and validated indicator of severity and
mortality risk in critical ill patients. This is an extremely
useful tool to characterize the study population properly,
and it will be determined by the research assistants in all
patients admitted to the study within 24 hours after the
hospital admission.
Organ dysfunction
The presence and severity of organ dysfunction is an
important prognostic variable in critical ill patients. Also,
the presence of organ dysfunction in a patient with sus-
pected or confirmed sepsis is defined as severe sepsis.
Hence, this variable is necessary to characterize the study
Table 2: Schedule of evaluations and data collection
Evaluation Screening Admission to the study Baseline evaluation First Week Daily during hospitalization and at 28-day
Clinical record review XX
Informed consent X
APACHE II score X
Organ dysfunction evaluation X
Study tests X
Definition of infection (CDC) X
Gold Standards X
Microbiological tests X
Vital status XBMC Infectious Diseases 2008, 8:18 http://www.biomedcentral.com/1471-2334/8/18
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population properly. The "surviving sepsis campaign"
together with the "Development of health care institute"
(Boston, MA, USA) have proposed a standard reference to
some parameters that define this population. The pres-
ence of at least one of the following organ dysfunction
variables constitutes a diagnosis of severe sepsis:
PaO2/FIO2 < 300
Urine output < 0.5 mL*kg-1*hr-1 or creatinine increase >
0.5 mg/dL
Serum creatinin > 2 mg/dL
International normalized ratio (INR) > 1.5 or aPTT > 60
secs
Platelet count < 100,000 μL-1
Plasma total bilirrubin > 4 mg/Dl
Tissue perfusion variables
Hyperlactatemia > 1 mmol/L
Metabolic acidosis (arterial pH<7.35 and PaCo2 normal o
low values) non explained caused
Hypotension
Systolic blood pressure < 90 mm Hg or mean arterial
blood pressure < 60 mm Hg. A 40 mm Hg descend respect
previous values.
Study tests (CRP, PCT, DD)
CRP, PCT and DD will be carried out in all patients twice,
at admission to the study and 24 hours after. These two
measurements will allow to estimate a kinetic of the mark-
ers related to the evolution time of the disease, and to
select the value that best reflects the chronology of the sys-
temic response to the infection. CRP and DD are stand-
ardized and routine tests performed in the hospital's
laboratory. The CRP is measured with a turbidimetry
assay and its values are reported as milligrams per deciliter
with a minimum value of 0.8 mg/dl. DD is measured with
a modified ELISA test and its values are reported as nano-
grams per milliliter. Values lower than 500 ng/ml are con-
sidered normal with this technique.
The BRAHMS PCT LIA © is an immunoluminimetric assay
used for determination of PCT in human serum and
plasma. This consists of adding two specific monoclonal
antibodies that link to the PCT in two different parts of the
molecule-Calcitonin and catalacin parts. One of the anti-
bodies is labeled by luminescence (trace), and the other
one is fixed inside a little tube (Coated Tube System). Dur-
ing incubation both antibodies react to PCT forming a
"sandwich complex", in this way the labeled antibody is
linked with the tube surface. The signal magnitude of the
luminescence is directly proportional to PCT concentra-
tion in the study sample. The analytic sensibility of the
assays is about 0.1 ng/ml and the functional sensitivity -
minimum measured value that diagnose with a maximum
precision of 20% of variance interassay- is about 0.3 ng/
ml. Lower values than 0.5 ng/ml are considered normal
with this technique.
Infection definition
The presence of infection, defined according with clinical
and microbiological criteria of the CDC definitions for
nosocomial infections, will be part of one of the "Gold
Standards" and will be determined by evaluation of three
independent experts, who will be blinded of CRP, PCT,
DD results.
Gold standards
Additionally to the microbiological confirmation and the
expert consensus, a LCA will be used to estimate the like-
lihood of sepsis.
Blood cultures and other microbiological studies
Two or more blood samples in different sites will be
obtained from all patients within 24 hours of admission
and before the beginning of the antimicrobial treatment
(In the case that the physician in charge decides to start
empirical treatment). The samples will be processed by an
automatized system for aerobic and anaerobic bacteria
(Bactec 9240, Becton, Dickinson and Co, New Jersey) and
the final report should include species and sensitivity to
antimicrobials. Other biological samples as sputum,
urine, pleural or peritoneal liquid or other kind of organic
samples, will be required and processed according to clin-
ical criteria for each patient and with the standard tech-
niques of the institution.
Vital status
During all hospital treatment and at 28-day, the vital sta-
tus will be observed in order to be able to estimate the glo-
bal mortality and for subgroups in the study population.
This determination will allow exploring the behavior of
the diagnostic tests according with different severity levels,
and also will allow evaluating their utility as prognostic
markers.
Discussion
Measuring diagnostic accuracy where there is no "gold 
standard"
The performance of a diagnostic test is judged by how
accurately the test result can identify a diseased or no dis-
eased person. The true disease status is the "gold stand-BMC Infectious Diseases 2008, 8:18 http://www.biomedcentral.com/1471-2334/8/18
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ard" against which a test should be compared. However,
there are many conditions for which the definitive diag-
nosis is very difficult or expensive to establish. This is
especially true for the diagnosis of a complex clinical con-
dition as sepsis, in which even within the construct of
"systemic response to infection" there is not a real "gold
standard" against which the diagnostic criteria can be cal-
ibrated [18].
Psychological and social sciences have a long tradition in
coping with primary study objects that are not directly
observable. Constructs such as intelligence, fear or trust
can only be measured indirectly. Inference proceeds by
modeling the relationship between observable and latent
variables in such a way that the parameters of interest are
estimable from the implied relations between observable
variables. When the unobservable variable is categorical,
the term latent class analysis (LCA) applies [6]. In other
words, LCA postulates the existence of an unobserved cat-
egorical variable that divides the population of interest
into classes. Members of the population with a set of
observed variables will respond differently depending on
the latent class to which they belong. This technique can
be applied to the problems related to diagnostic testing,
with the unobserved categorical variable being "disease
present" or "disease absent" [44]. The observed variables
might typically be the results of three or more diagnostic
tests, none of them being a gold standard. LCA can then
be applied to estimate the proportions of patients in each
latent class (that is, estimated to be diseased or free of dis-
ease), and the sensitivity and specificity of each diagnostic
test. In summary, the goal of latent class analysis is to use
the observed probabilities to estimate the unobserved
ones.
The methodology for latent class analysis is one of the
most active areas of biostatistics research and develop-
ment in the last years [44-50], and specialized software is
available for estimation procedures [10,11]. Considering
the importance to have a diagnostic test that got a mini-
mal proportion of false negative results, we have consid-
ered the sensitivity estimation to calculate the sample size.
An adequate precision of the sensibility value gives
enough power to detect significant values in the other
operative characteristics. The number of the patients with
the disease (NP) that is needed to give a sensibility estima-
tion of 95%, with a 95% confidence interval +/- 3% is cal-
culated with the following formula [51]:
The NP (true positives and false negatives) is also deter-
mined by the prevalence (P) of the disease in the study
population. Hence, the total of patients (TP) required for
this research is a function of these two amounts:
According with the inclusion and exclusion criteria
defined for our study population, the expected prevalence
of microbiological confirmed sepsis is about 30% [3,15].
Therefore, the total participants we should recruited for an
adequate sample size is 677 patients. Considering the
necessity to carry out a pilot test to standardize PCT meas-
urement, the total of patients recruited will be 700.
The cut points for the study tests (CRP, PCT, and DD) will
be explored using Receptor Operative Characteristics
(ROC) curves [52], using as classification criteria the gold
standard clinical tests (presence of infection defined
according with CDC modified criteria, and sepsis diagno-
sis defined as clinical consensus), but also using the pres-
ence of severe sepsis (organ dysfunction) and mortality.
This will allow defining the cut points with the best sensi-
bility without compromising the specificity significantly,
but also to define useful values in clinical decisions.
A conventional method based in Bayes Theorem will be
used to determine the operative characteristics of the tests
and their different combinations against the referred gold
standards [53]. 95% confidence intervals will be esti-
mated for values of sensitivity, specificity, predictive val-
ues and likelihood ratios. STATA software (Stata Co,
release 8.2, College Station, TX, USA, 2004) will be used
for all analysis.
LCA is a statistical method developed to find subtypes of
related cases (latent classes) that are inherent and implicit
within multivariable categorical data [6]. A particularly
application of the LCA is the evaluation of the accuracy of
diagnostic tests when there is a lack of a "gold standard".
In presence of at least three tests -CRP, PCT, DD- that can
detect presence or absence of an illness, but without any
of them that can determine certainly the condition; the
LCA could be used to estimate the diagnostic accuracy of
these tests. The traditional LCA assumes that results from
the three tests in the same subject are independent within
the real condition of illness [44]. In other words, the con-
ditional or local independence assumption affirms that
inside each latent class (sepsis or no sepsis); each result of
a test is statistically independent of the result of the other
one. If the effect to belong to a latent condition of sepsis
would be removed, the effects to the CRP, PCT and DD
would have a completely random distribution in the
study population. However, in many clinical situations
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this independence assumption is less likelihood and in
some cases is extremely difficult to verify. In our study it is
probably that PCT and CRP values are related directly
each other within an inflammation process.
This local independence assumption can be relaxed or
controlled introducing a random effect through a contin-
uous latent variable [47]. In the LCA with random effects,
it is assumed that the result of diagnostic tests is control-
led by two mechanisms or factors. The first one is the real
condition of the illness (δ) and the second one is the bio-
logical individual process in the patient or the technical
characteristics of the test. In this regard, the model intro-
duces another latent variable (t) that summarizes or rep-
resents the subject or the diagnostic test attributes that are
not explained by the real condition of the illness. Hence,
it is assumed that the results of the different diagnostic
tests are independent, conditionals in δ and t. Similarly, it
is assumed that t is distributed according to a standard
normal distribution and that the probability to have a
positive result from the test (Pr Y = 1), given δ, is a monot-
onic function of t, this is represented by the following
equation:
Pr(Yi = 1|δ, t) = Φ(aiδ + bδt)
In this equation, "Φ", represents the function of the accu-
mulated density of the normal distribution, and the a and
b terms are the parameters. The positive rate of the test,
conditionally in δ, is simply the mean value over t. The
estimators of maximum verisimilitude for sensibility and
specificity of each test could be obtained with an integral
that uses an iteration algorithm such as the EM or the
Newton-Rapson method [46,47]. All the previous analysis
and convergence procedures to the latent class estimation
will be carried out with the statistical software Latent
GOLD 4.0 (Statistical Innovations, Belmont, MA, USA)
The existence of two clinical "gold standards", as previ-
ously described, will allow us to compare them against the
LCA results. In this way it is possible to analyze the differ-
ences and similarities when sepsis diagnosis is defined by
LCA comparing by clinical consensus or simple infection
criteria. Thus, the strong biological assumption of a cross-
talk between inflammation and coagulation in sepsis, and
a sensible mathematical model of the latent diagnostic
classification, provide a unique opportunity to under-
stand a relevant clinical and public health problem.
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